Answers are grounded in this paper and cite their sources.
The urothelial barrier regulates access of urinary solutes to bladder tissue and its immune microenvironment. This review evaluates urinary composition, epithelial transport, urothelial sensing, immune regulation and tumor or treatment outcomes as a linked causal sequence. Bladder studies establish barrier injury responses, epithelial ATP signaling and BCG-induced tissue immune pathways; human tumor explants provide functional evidence for a BCG–COX2/PGE2/EP4 chemokine circuit. Quantitative comparisons identify the unresolved step between urinary abundance and immune-cell exposure: urinary adenosine averages approximately 4.75 μM in one healthy cohort, whereas T-cell responses vary with dose and exposure duration; pooled urinary kynurenine averages approximately 2.48 μM, compared with a 50 μM dose used in a non-bladder AhR reporter assay. Tissue delivery was not measured in these studies. We describe three permeability states using experimental barrier measurements, distinguish reversible immune adaptation from lineage-resolved selection, and propose a urinary exposure × epithelial permeability interaction. Paired urine–tissue measurements, flux assays and longitudinal clonal tracking can test whether luminal exposures independently drive or modify bladder cancer immunity and treatment response.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: